We are adding Merck & Co. (NYSE: MRK) to the Global Income Edge Conservative Portfolio.  

In a continuation of our focus on solid health care stocks that we will provide solid dividend income, we found Merck & Co. to be undervalued now after the latest market declines and a management shakeup has increased the company’s commitment to new drug discovery, particularly for diseases with few, or even any, effective treatments.

My colleague Ben Shepherd, an expert in the healthcare sector, provides a deep-dive on the value proposition of the firm in our October 2015 Global Income Edge issue, which recently published.

With a dividend yield of 3.5%, MRK is a Buy up to $65